Cartesian Therapeutics, a biotech seeking to develop mRNA cell therapies for autoimmune diseases, was trading nearly 20% lower early in Tuesday’s trading. 3 July 2024
With the annual meeting of the American Society of Clinical Oncology (ASCO) now just days away, multiple large drugmakers have lifted the lid on data that they 29 May 2024
Contract research organization IQVIA has published its Global Oncology Trends report for 2024, projecting a significant rise in cancer cases. 29 May 2024
Less than two years after it was launched, San Francisco-based startup Cartography Biosciences has announced a deal with nearby biotech major, Gilead Sciences. 29 May 2024
Sapreme, a Dutch biotech developing next-generation RNA therapeutics for genetically-driven diseases, has appointed Marco Timmers as chief executive. 28 May 2024
Australia’s Neuren Pharmaceuticals has announced top-line results from its Phase II trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). 28 May 2024
The US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Sarclisa (isatuximab) along 28 May 2024
Oncology-focused biotech company Tango Therapeutics is to discontinue development of its TNG348 program due toxicity observed in the initial study cohorts. 24 May 2024
Californian company Cytokinetics closed Thursday’s trading down 17% after announcing a couple of updates that will add $1 billion to its cash pile. 24 May 2024
SynaptixBio, a UK biotech that claims to be the world’s only company developing a therapy for TUBB4A-related leukodystrophies, has appointed Uwe Meya as chief m 23 May 2024